Sign up United Kingdom
Proactive Investors - Run By Investors For Investors unit abandons plan to sell pharmaceutical products, CNBC says

Amazon found it difficult to persuade hospitals to change the way they purchase products box
Amazon Business failed to convince hospitals to change the way they purchase products Inc.'s (NASDAQ:AMZN) Business unit, which sells bulk items to companies, has abandoned a plan to sell pharmaceutical products after weighing it last year, according to a report by CNBC, citing people familiar with the matter.

Amazon Business’s decision is partly because it failed to persuade hospitals to change the way they purchase products and cut out middlemen from the deals, CNBC said.

Another issue was that Amazon Business would have had to build an extensive logistics network that could accomodate drugs and other pharmaceutical products, which are sensitive to temperature, according to the report.

The retreat from the pharmaceutical space was seen as favorable by investors in pharmacies. CVS Health Corp. gained 5.7% to US$67.00 in early afternoon trading, while the Walgreens Boots Alliance Inc., which owns Walgreens and Boots, jumped 4.1% to US$66.43.

Amazon Business may consider getting into pharmaceuticals again as it gains size, according to CNBC.

Shares of were up 0.64% at US$1,439.50.

View full AMZN profile View Profile Timeline

Related Articles

H&T Pawnbrokers store
July 02 2018
Last year the company saw gross profits jump 45% thanks to a booming personal loan book and robust sales of luxury second-hand watches and jewellery.
Flying Brands
July 17 2018
“We look forward to the future with confidence and excitement," said Flying Brands boss Trevor Brown.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use